AI-generated summary
The authors reviewed a public U.S. FDA database of low-level laser therapy devices cleared between 2000 and 2018 for androgenetic alopecia. They report that 47 devices received 510(k) premarket clearance, with more devices available since 2007 and indications expanding to include both men and women. The authors also state that marketed indications have not been adequately explored and may mislead consumers.
- Who or what was studied
- Low-level laser therapy devices cleared by the U.S. FDA for androgenetic alopecia
- Limits stated in the abstract
- The study reviews regulatory clearance records and does not assess the clinical efficacy or safety of the devices.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on tandfonline.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Low-level laser therapy, Laser, Androgenetic alopecia, Light-emitting diode. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.